v3.26.3
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Operating expenses:        
Research and development $ 64,359 $ 49,139 $ 165,791 $ 103,752
General and administrative 22,245 9,935 54,755 38,525
Change in fair value of contingent milestone liabilities (21,789) 0 21,740 0
Total operating expense 64,815 59,074 242,286 142,277
Loss from operations (64,815) (59,074) (242,286) (142,277)
Other income (expense):        
Interest income 6,236 1,471 11,794 3,371
Change in fair value of preferred stock tranche obligations 0 5,012 0 1,100
Bargain purchase gain 0 0 0 5,232
Warrant issuance expense 0 (7,358) 0 (7,358)
Other income (expense), net 11 (207) (383) 145
Loss before income taxes (58,568) (60,156) (230,875) (139,787)
Income tax benefit 0 0 0 4,167
Net loss $ (58,568) $ (60,156) $ (230,875) $ (135,620)
Net loss per share attributable to common stockholders, basic $ (0.64) $ (4.43) $ (5.22) $ (10.8)
Net loss per share attributable to common stockholders, diluted $ (0.64) $ (4.43) $ (5.22) $ (10.8)
Weighted average common shares outstanding used in calculating net loss per share attributable to common stockholders, basic 92,072,013 13,574,615 44,219,136 12,559,797
Weighted average common shares outstanding used in calculating net loss per share attributable to common stockholders, diluted 92,072,013 13,574,615 44,219,136 12,559,797
Other comprehensive loss        
Unrealized loss on investments $ (1,871) $ (53) $ (2,169) $ (53)
Total comprehensive loss $ (60,439) $ (60,209) $ (233,044) $ (135,673)